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Myotonic dystrophy (DM) is a multi-system neuromuscular disorder for which there is no treatment. We have
developed a medium throughput phenotypic assay, based on the identification of nuclear foci in DM patient
cell lines using in situ hybridization and high-content imaging to screen for potentially useful therapeutic com-
pounds. A series of further assays based on molecular features of DM have also been employed. Two
compounds that reduce and/or remove nuclear foci have been identified, Ro 31-8220 and chromomycin A3.
Ro 31-8220 is a PKC inhibitor, previously shown to affect the hyperphosphorylation of CELF1 and ameliorate
the cardiac phenotype in a DM1 mouse model. We show that the same compound eliminates nuclear foci,
reduces MBNL1 protein in the nucleus, affects ATP2A1 alternative splicing and reduces steady-state levels of
CELF1protein.Wedemonstrate that this effect is independent of PKCactivity and conclude that this compound
may be acting on alternative kinase targets within DM pathophysiology. Understanding the activity profile for
this compound is key for the development of targeted therapeutics in the treatment of DM.
INTRODUCTION
Myotonic dystrophy (DM) is the most common muscular dys-
trophy in adults (1). It consists of two different types, both of
which are caused by repeat expansion mutations and both of
which share a common molecular basis (2). Although there are
some clinical differences, DM1 and DM2 are progressive
neuromuscular disorders in which patients suffer from
myotonia, muscle weakness and wasting, and often a variety
of other symptoms including cardiac arrhythmias, diabetes,
and cataracts (2).
Both forms of DM are dominantly inherited. DM1 is caused by
a CTG repeat sequence located in the 3′ untranslated region of
the DMPK gene. In the unaffected population, the repeat is
present as 5–30 copies, whereas in DM1 patients it is present
between 50 and several thousand copies (3–5). The severity of
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the disease shows a general correlation with repeat expansion
length. DM2 is caused by a tetranucleotide repeat expansion
(CCTG) sequence present in the first intron of another gene,
CNBP. The repeat is present as tens of copies in the normal popu-
lation and as several thousand copies in DM2 patients (6).
The molecular events underlying DM pathophysiology can be
broken down into a series of stages. In both forms of DM, expan-
sion of the repeat sequences, when transcribed, produces RNAs
that aggregate and remain within the nuclei of DM patient cells
where they appear as distinct foci (7–9). Two groups of proteins
are affected by the CUG or CCUG repeat-containing RNAs. The
Muscleblind-like proteins (MBNL) are sequestered by repeat
expansion transcripts (10–12), whereas CELF1 is not seques-
tered, but activated in DM1 by the mutant repeat expansion
RNA (13). CELF1 and MBNL proteins are involved in the regu-
lation of alternative splicing. Transcripts, such as cardiac tropo-
nin T (TNNT2) (14), muscle-specific chloride channel (CLCN1)
(15), insulin receptor (INSR) (16), sarcoplasmic/endoplasmic re-
ticulum Ca2+-ATPase (ATP2A1) 1 (17) and several others (18),
are mis-spliced, resulting in an imbalance of isoforms whichcon-
tributes to the DM phenotype. Multiple mechanisms are affected in
response to RNA toxicity in DM cells and recent work points to a
role for translational inhibition due to CUG repeat RNA-induced
stress in DM1 (19,20). Evidence demonstrating alterations to chro-
matin structure, bi-directional transcription and non-ATG-initiated
translation suggests that disruption of multiple molecular pathways
may contribute to the DM phenotype (21,22).
There is currently no treatment for either form of DM, but an
emerging understanding of the molecular basis of these disorders
allows the rational development of assays to identify therapeutic
compounds not currently available for the treatment of DM. This
has led to the publication of biochemical and oligonucleotide-
based approaches to identify compounds that target the repeat
expansion sequences and disrupt the interaction between
MBNL and the repeats (23–28). Other studies report the use of
cell-based assays in conjunction with fluorescent splicing repor-
ters for compound screens (29,30). In the present study, we de-
scribe a medium throughput screen for small molecules that
may have therapeutic benefit in DM. We have established a com-
pound screening protocol with high-content imaging of nuclear
foci in immortalized DM cells using an in situ hybridization-
based approach. We have screened the NIH Chemical Genomics
Center (NCGC) Pharmaceutical Collection (NPC), a Chem-
bridge DiversetTM library and two smaller collections of phos-
phatase and kinase inhibitors to identify two compounds that
eliminate nuclear foci and may have potential for further devel-
opment as DM therapies.
RESULTS
Primary screen for compounds that remove nuclear foci
The general screening strategy we have adopted consists of four
different levels to provide insight to various aspects of DM
pathophysiology (Supplementary Material, Fig. S1). For the
primary screen, we used an in situ hybridization-based protocol
to identify nuclear foci in telomerized DM patient fibroblast cell
lines (Supplementary Material, Fig. S2). Fibroblast cultures
established from DM patients and controls were infected with
an engineered lentivirus to express constitutively sufficient
levels of telomerase for continuous growth in culture over
extended periods of time as described previously for other
cells (31). Some of the cell lines were also transduced with a
lentivirus containing a construct that allows inducible expres-
sion of the myogenic regulatory factor MyoD, which when
expressed converts fibroblasts into myogenic cells (31). The
in situ hybridization screening protocol was implemented to
score nuclear foci on a Molecular Devices Micro plate reader
using a modified version of the granularity analysis journal. Typ-
ically fibroblast cells from DM1 patients (KBTeloMyoD) have
an average of three to five foci per cell, whereas fibroblast
cells from DM2 (KagoTelo) patients have between 5 and 11
foci per cell. Data were transferred to an excel spreadsheet and
for each plate in the primary screen we calculated the mean
number of foci per well in the control (DMSO treatment-only)
wells and scored as positive any compound-treated wells that
produced a change in foci number of .2 SD from the mean.
Four different libraries were screened including 13 200 com-
pounds from a Chembridge DiversetTM library, 2724 com-
pounds from the NPC library and two smaller libraries from
Enzo Life Sciences consisting of 80 kinase inhibitors and 33
phosphatase inhibitors. Supplementary Material, Table S1
shows the numbers of compounds screened and the numbers
taken forward to secondary and further assays. Following the
primary screen 364 small molecules were chosen for secondary
validation from the Chembridge DiversetTM library and 120
from the NPC library. Three compounds were selected for
further analysis from the kinase inhibitor library. None of the
compounds in the phosphatase inhibitor library produced a sig-
nificant change in foci.
Secondary screens for compounds to remove or reduce
nuclear foci
Compounds that changed nuclear foci number by .2 SD from
the mean of the DMSO-treated control wells were cherry-picked
for a confirmation study. These compounds were screened in a
12-point titration ranging from 200 pm to 40 mm in duplicates
to determine their concentration response on reduction or in-
crease of foci. Following in situ hybridization, images were col-
lected on the Molecular Devices Micro plate reader and analysed
to score nuclear foci number. All images from the secondary
screen were also confirmed by direct visualization by more
than one individual. In addition, compounds were tested for
any effect on cytotoxicity, cell viability and apoptosis using
the Promega ApoTox-Glo Triplex assay to determine whether
the reduction in nuclear foci was due to general compound tox-
icity to the cells.
Of the 120 compounds from the NPC library, 17 produced a
significant increase in foci in either DM1 or DM2 cells, or
both. These included meclocycline which appeared specific for
DM1, teroxironum and topotecan, both of which had a more
marked effect on DM2 foci. Merbromin produced a significant
increase in foci, for both DM1 and DM2 (Supplementary Mater-
ial, Fig. S3). From this library gemcitabine (a nucleoside ana-
logue) and chromomycin A3 (a glycosidic antibiotic) reduced
foci in both DM1 and DM2 cells. Multiple other nucleoside ana-
logues tested had no effect (Supplementary Material, Fig. S4).
Three of the 80 compounds from the kinase inhibitor library;
GF 109203X, hypericin and Ro 31-8220 produced a reduction in
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foci in the primary screen. Of these, GF 109203X only produced
a reduction in foci numbers at the very highest concentration.
Most of the compounds were excluded from further consider-
ation, including the 364 hits from the Chembridge library,
because either they failed to replicate in the secondary screen
or they affected cell viability, produced cytotoxicity or apoptosis
over the efficacious concentration range.
Following the secondary screening four compounds demon-
strated a significant reduction in foci number over the dilution
range (Fig. 1A–E). Two of the compounds identified; gemcita-
bine and hypericin showed toxicity profiles that matched the dis-
appearance of foci. Ro 31-8220 and chromomycin A3 reduced
foci numbers at concentrations that did not have a fully matching
toxic effect although the viability of the cells was reduced rela-
tive to controls (Fig. 2A–D). Chromomycin A3 showed the
clearest difference between reduction in foci and toxicity over
2 day exposure (Figs 1E and 2D), whereas Ro 31-8220 showed
a higher toxicity overall but a sharper reduction in foci over a
narrow concentration range (Figs 1C and 2B). To assess the
effects on other DM cell lines compounds were applied at
three concentrations to three different DM1-derived myoblast
lines; DM15, DM16 and DM1400 (25) and similar results
were obtained (Supplementary Material, Fig. S5). Thus, Ro
31-8220 and chromomycin A3 were chosen for further analysis.
To assess whether these compounds affected other aspects of
DM pathophysiology they were subjected to four additional
assays to examine nucleo-cytoplasmic MBNL protein distribu-
tion, alternative splicing, mutant transcript location and levels,
and in vivo effects on a zebrafish CUG expansion model.
Effect of compounds on MBNL1 nucleo-cytoplasmic
distribution
The consensus model of DM pathogenesis suggests that MBNL
proteins are sequestered in nuclear foci and as a consequence al-
ternative splicing is impaired (32). Thus, we used western blots
to examine the distribution of MBNL1 protein in nuclear and
cytoplasmic fractions of DM cells before and after treatment
with chromomycin A3 and Ro 31-8220. Initial analysis revealed
Figure 1. Compound treatments reduce nuclear foci. (A–E) Images of KBTeloMyoD fibroblast cells (DM1) and KagoTelo fibroblast cells (DM2) following RNA
FISH using Cy3-(CAG)10 probe (green) for the localization of the mutant transcript and Hoechst (blue) to indicate the cell nucleus. Treatment with (A) DMSO,
(B) hypericin (4.4 mm), (C) Ro 31-8220 (4.4 mm), (D) gemcitabine (4.4 mm) and (E) chromomycin A3 (4.4 mm).
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that DM cells show a greater proportion of MBNL1 in the nuclear
fraction compared with non-DM cells. In both DM1 and DM2
cells the proportion of nuclear MBNL1 was at least 50% greater
than observed in non-DM cells (Fig. 3A and B). Treatment
with chromomycin A3 and Ro 31-8220 resulted in reduced
total protein levels in KBTeloMyoD (DM1 fibroblast) and
DM15 (DM1 myoblast) cell extracts (Supplementary Material,
Table S2). Treatment of DM1 fibroblasts (Fig. 3C) and myo-
blast cells (Fig. 3D) with each compound significantly
altered the ratio of nuclear to cytoplasmic MBNL1 compared
with that observed in DMSO-treated DM1 cells (Fig. 3E) with
the ratios being more similar to those observed in non-DM
cells. To examine the effect of compound treatment on the
MBNL1 protein content of nuclear foci, we performed im-
munocytochemistry of DM1 cells before and after exposure
to chromomycin A3 and Ro 31-8220. Consistent with their
effect on RNA foci and the depletion of MBNL1 from the
nuclear compartment of DM cells, both compounds signifi-
cantly reduced MBNL1 in foci (Supplementary Material,
Fig. S6). Thus, nuclear foci disappear as MBNL1 is depleted
from the nucleus of DM cells.
Effect of compounds on alternative splicing
One of the best described molecular features of DM is an imbal-
ance of alternatively spliced isoforms for various transcripts (32)
and we would predict that reductions in nuclear foci and the
concomitant reduction in nuclear sequestration of MBNL
would reverse splicing abnormalities observed in DM. Thus,
we have selected two examples of MBNL-dependent splicing
abnormalities to test the effect of compound treatment. INSR
mis-splicing has been linked to the insulin resistance phenotype
in DM patients (33). MBNL1 is the primary determinant in INSR
splicing and although CELF1 does contribute, it is thought to be
secondary to the role of MBNL1 (34). Work from others has
shown that one of the most notable splicing changes in DM1 is
the imbalance of ATP2A1 transcript isoforms (17,18), which is
MBNL1 dependent in muscle cells (35). We used assays for
both of these transcripts as a read-out of the effect of drug treat-
ment to determine whether chromomycin A3 and Ro 31-8220
reverse DM-associated alternative splicing defects. DM1 fibro-
blast cells with inducible MyoD were differentiated to myoblasts
and treated with chromomycin A3 and Ro-31-8220 at concentra-
tions of 40 nm and 10 mm respectively, for 48 h, and the result-
ing splicing profiles analysed. In DM1 cells INSR is mis-spliced
such that there is an increase in the minus exon 11 isoform (33).
Following compound treatment with both chromomycin A3 and
Ro 31-8220 the minus exon 11 isoform was significantly reduced
when compared with DMSO-only treated DM1 samples (Fig. 4A
and B).ATP2A1 is mis-spliced in DM1 differentiated fibroblasts
with a substantial over-representation of the exon 22-minus
isoform (18), whereas the ATP2A1 exon 22-plus transcript pre-
dominates in non-DM differentiated cells (Fig. 4A and C). Chro-
momycin A3 treatment did not produce a significant reduction
Figure 2. Compound treatment and toxicity profiles. Standard concentration curves showing the effect of compound treatments in KBTeloMyoD cells (DM1) and
KagoTelo cells (DM2) in which the percentages of foci (green) and cell viability (blue) are represented relative to DMSO treatment on the ‘y’-axis. Compound
concentration (log mm) is indicated on the ‘x’-axis for hypericin (A), Ro 31-8220 (B), gemcitabine (C) and chromomycin A3 (D).
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in the minus exon 22 form of ATP2A1. However, Ro 31-8220
produced a significant decrease (P–value ,0.0002) in the rela-
tive proportion of the exon 22-minus ATP2A1 transcripts in the
DM cell line (Fig. 4A and C).
The data suggest that treatment with both compounds can
affect DM associated mis-splicing in INSR, although only Ro
31-8220 significantly shifts ATP2A1 splicing towards the
distribution of non-DM cells.
Effect of compounds on the mutant transcript
To determine whether Ro 31-8220 and chromomycin A3 affect
the mutant repeat expansion transcripts, we utilized an R/T PCR
assay developed previously (7) which distinguishes the mutant
and wild-type DMPK transcripts based on the presence or
absence of a coding BpmI polymorphism in conjunction with
nuclear and cytoplasmic RNA fractionation. Initially, products
were visualized on ethidium-stained gels (Fig. 5A) to compare
mutant and wild-type DMPK transcripts. Analysis of RNA
from DM1 cell line KBTeloMyoD showed that although the
mutant transcript was present in the nuclear fractions there was
no indication of the mutant transcript in the cytoplasmic frac-
tions before and after treatment with chromomycin A3 and Ro
31-8220 (Fig. 5A). To provide quantitative confirmation of
this result and measure the relative proportion of mutant and
wild-type DMPK transcripts in the nucleus and cytoplasm, quan-
titative RT–PCR was performed using Genescan analysis fol-
lowing amplification and BpmI restriction enzyme digestion
(Fig. 5B). Around 10% of the population are informative for
the BpmI polymorphism embedded within DMPK and cell line
SBTeloMyoD was established from a person who did not have
DM but who is heterozygous for the BpmI polymorphism. As
Figure 3. The subcellular distribution of MBNL1. (A) Western blots showing the distribution of MBNL1in nuclear (N) and cytoplasmic (C) compartments of cell lines
NIRATelo (control), KBTeloMyoD (DM1) and KAGOTelo (DM2). (B) Histograms show data compiled from intensity scans of triplicate blots for each cell line,
normalized against values for lamin-B and tubulin. (C and D) Western blots showing the distribution of MBNL1 in nuclear (N) and cytoplasmic (C) compartments
of fibroblast cell line KBTeloMyoD (DM1) (C) and DM1 myoblast cell line DM15 (D) following treatment with Ro 31-8220 (10 mm), chromomycin A3 (40 nm) and
DMSO. (E) Histogramsare shown of datacompiled from intensity scansof triplicate blots for cell lines KBTeloMyoD and DM15 following treatment with Ro 31-8220
(10 mm), chromomycin A3 (40 nm) and DMSO normalized against values for lamin-B and tubulin.
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such they provide a control for the distribution of transcripts with
and without the BpmI polymorphism. Figure 5B shows clearly
that both types of transcript, with and without the BpmI site,
are present in nuclear and cytoplasmic compartments of
non-DM cell line SBTeloMyoD. The histograms show that chro-
momycin A3 has no effect on the nuclear retention of the repeat
expansion transcript or on the relative proportions of mutant and
wild-type DMPK transcripts in the nucleus (Fig. 5B). Similarly,
Ro 31-8220 does not affect the absence of the mutant transcript
from the cytoplasm. However, it does produce a slight reduction
in the relative amount of the mutant transcript in the nucleus of
KBTeloMyoD (Fig. 5B). Although foci disappear there is no
evidence from the analysis of cytoplasmic RNA to support the
liberation of the mutant transcripts from the nucleus to the
cytoplasm following treatment with either compound.
The effect of compounds in a CUG-repeat expansion
zebrafish model
To support the screen for DM therapeutic compounds, we have
developed a transgenic CUG-repeat expansion zebrafish
model, in which (CUG)140 repeat transcripts are injected into
zebrafish embryos (Supplementary Material, Fig. S7). This
model has not been characterized beyond the external pheno-
type; however, a recent publication describing a transient zebra-
fish embryo model with 91 CUG repeats demonstrates the
presence of nuclear foci and a global down-regulation of muscle-
specific developmental transcripts following injection of repeat
RNA (36). The phenotype replicates the model used in this study
suggesting its suitability as a basic in vivo model for DM1.
Embryoswerescoredaccording to thenumberof somitesobserved
beyond the yolk cell extension and the length to width ratio of the
tail beyond the yolk cell extension. Uninjected control embryos
Figure 4. The effect of compound treatment on INSR and ATP2A1 alternative splicing. (A) Ethidium-stained agarose gels show RT–PCR fragment analysis of INSR
and ATP2A1 splicing in DM differentiated fibroblast cell lines compared with non-DM differentiated fibroblast cells following treatment with Ro 31-8220 (10 mm),
chromomycin A3 (40 nm) and DMSO (control). (B) Histograms show the percentage of INSR transcripts with the minus exon 11 isoform following compound treat-
ment. (C) Histograms show the percentage of ATP2A1 transcripts with the minus exon 22 isoform following compound treatment. In each case, the data represent
separate measurements produced for three biological replicates. Statistical analysis demonstrates the significance of compound treatments on both INSR and ATP2A1
splicing profiles towards that of the non-DM form.
Figure 5. The effect of compound treatment on repeat expansion transcripts. The
relative proportions of the mutant and wild-type DMPK transcripts in KBTelo-
MyoD differentiated fibroblast cells (DM1) were assessed following treatments
with Ro 31-8220 (10 mm), chromomycin A3 (40 nm) and DMSO control.
(A) Ethidium bromide-stained gel showing RT–PCR products from nuclear (N)
and cytoplasmic (C) RNA fractions of KBTeloMyoD cells following the amplifi-
cation andBpmI restriction enzyme digestion of a fragment of DMPK. GAPDH is
used as a loading control. (B) Histograms showing the relative proportions of
mutant (BpmI positive) and wild-type (BpmI negative) nuclear DMPK transcripts
expressed as a percentage of the total nuclear DMPK transcripts. Quantitative
RT–PCR was conducted using Genescan analysis of areas under the peaks follow-
ing amplification of DMPK and BpmI restriction enzyme digestion.
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were treated withRo31-8220 at 5 mm for 24 h and evaluated in the
same way. There is a very mild negative effect on the phenotype of
these embryos with the average somite number being 10% lower
than untreated embryos. The length:width ratio effect was mild
and reduced by 4% compared with untreated embryos. The
effects of compound treatment in vivo were measured against
repeat RNA-injected, non-compound-treated embryos. Because
of its size chromomycin A3 did not penetrate effectively the zebra-
fish chorion, so it was not studied further in this assay. The CUG140
RNA reduced the somite number and length to width ratio by 40%
compared with uninjected controls. Treatment with 5 mm Ro
31-8220 had a beneficial effect, with partial rescue of the mutant
phenotype (Supplementary Material, Fig. S7E and F). Seventy
embryos were scored in each category and the difference
betweenCUG140 embryos andRo31-8220-treatedzebrafish is sig-
nificant for both somite number and length to width ratio with a
P-value of ,0.0001.
The effect of compounds on foci is not mediated by PKC
The phenotypic effect of Ro 31-8220 on a zebrafish embryo
model is consistent with the beneficial effect of this inhibitor
on the cardiac phenotype observed in a DM1 mouse model
(37). Ro 31-8220 is a PKC inhibitor and recent work indicates
that inappropriate activation of the PKC pathway is a factor in
DM pathogenesis (13,37).
Figure 6. Comparing the effects of Ro 31-8220 and GF 109203X. The structure of GF 109203X is shown in (A) and Ro 31-8220 in (B). (C) Images of KBTeloMyoD
fibroblast cells (DM1) are shown following treatment with Ro 31-8220 at 10 mm, DMSO and GF 109 203X at 40 mm. (D) The standard concentration curves for GF
109 203X treatment of KBTeloMyoD fibroblast cells in which the percentages of foci (green) and cell viability (blue) are represented relative to DMSO treatment.
(E) Histogram showing nuclear and cytoplasmic distribution of MBNL1 following GF 109 203X treatment. The graph shows the combined data of triplicate samples
for comparison of GF 109 203X and DMSO treatments. (F) The alternative splicing patterns of ATP2A1 obtained for untreated SBTeloMyoD differentiated fibro-
blasts (non-DM cells) (lane 1), KBTeloMyoD differentiatedfibroblasts (DM1) treated with DMSO(lane 2) and KBTeloMyoD differentiated fibroblasts (DM1) treated
with GF 109 203X (lane 3).
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To establish if the effect of Ro 31-8220 treatment in our cell
system is PKC dependent, we studied additional PKC inhibitor
compounds. We tested a series of 12 structurally related com-
pounds in the nuclear foci assay in both DM1 and DM2 fibroblast
cells (Supplementary Material, Fig. S8A). At the very highest
concentration (40 mm) two of the bisindolylmaleimides (VI
and II) demonstrated a slight reduction in foci but had no
effect at lower concentrations. All other PKC inhibitors tested
had no effect across the 12 point concentration range (Supple-
mentary Material, Fig. S8B and C). Interestingly, we observed
that GF 109203X, although structurally very similar to Ro
31-8220, (Fig. 6A and B) demonstrated different effects on
nuclear foci. Ro 31-8220 is effective at disrupting foci at a con-
centration of 2.5 mm, whereas GF 109203X has only a slight
effect at the highest applied concentrations and no effect at con-
centrations,40 mm (Fig. 6C and D). The effect of GF 109203X
was compared with that of Ro 31-8220 in two of the tertiary
assays. We compared their effects on Muscleblind-like distribu-
tion andATP2A1 alternative splicing ratios. Ro 31-8220 changes
the nuclear to cytoplasmic distribution of muscleblind, decreas-
ing the amount of nuclear MBNL1 (Fig. 3C and E), whereas GF
109203X does not (Fig. 6E). Treatment with GF 109203X has no
beneficial effect on the ratio of alternative splice isoforms of
ATP2A1 observed in the DM cell line KBTeloMyoD when com-
pared with DMSO treatment (Fig. 6F). This contrasts with the
effect of Ro 31-8220 which produces a correction in the splicing
profile (Fig. 4). These data demonstrate that PKC inhibition by
Ro 31-8220 is not responsible for the effects observed on
MBNL-dependent events in our DM cell lines.
Previous work has described the role of PKCa in a DM mouse
model system and the destabilization of CELF1 protein follow-
ing Ro 31-8220 treatment (36). To verify the effect of Ro
31-8220 and GF 109203X on CELF1 protein levels in our
patient cell model, we conducted western blot analysis on tripli-
cate samples following compound treatment. Consistent with
previous reports treatment with Ro 31-8220 resulted in a 91%
reduction in CELF1 protein. However, we found there to be
only a 48% reduction in the level of this protein following treat-
ment with GF 109203X (Fig. 7A and B). A comparison of the
PKCa IC50 values for these two compounds demonstrates that
GF 109203X is more potent on this target (IC50 8 nm) then Ro
31-8220 (IC50 33 nm) (37,38). To establish the effect of
PKCa on CELF1 levels in our cell model, we performed
siRNA knockdown of PKCa . We achieved 61% reduction of
protein but found there to be no difference in CELF1 levels fol-
lowing knockdown, suggesting this kinase is not responsible for
the results observed (Fig. 7C). Likewise, PKCa knockdown did
not reduce the number of nuclear foci (data not shown). These
data suggest that the effect on nuclear foci, MBNL-dependent
events and CELF1 protein steady-state levels are not due to
PKC inhibition in our cell system.
DISCUSSION
The identification of compounds to treat inherited diseases repre-
sents a major challenge because the precise mechanism of patho-
physiology for many of these rare conditions is still unclear and
there has been a lack of major effort for drug development. Thus
far, several approaches have been used to identify potential
therapies for DM (23,24,26,27,38–40) including two cell-based
studies using splice reporter systems (30,41). Although DM is
often quoted to be a spliceopathy (42), in terms of the sequence
of events underlying the disorder, splicing abnormalities arise at
a later stage of the molecular pathway. One of the earliest events
in DM pathophysiology occurs when repeat expansion RNA is
transcribed and accumulates in the nuclei of DM cells, where
it sequesters MBNL proteins, forming characteristic spots or
foci (9). We have developed a phenotypic assay to screen for po-
tentially useful therapeutic compounds for DM, based on the
elimination of nuclear foci using an in situhybridization protocol
and high-content imaging of DM patient cell lines. We have
screened four libraries including three that are commercially
available and the NPC library. Although multiple hits were iden-
tified initially from the Chembridge DiversetTM library, none
validated in the secondary screen, which combined a concentra-
tion/dilution series with tests for cell viability. In many cases the
concentration range over which foci were affected, matched very
closely the concentration range that killed the cells. Thus, the dis-
appearance of foci in these cases was probably due to cell death.
Figure 7. The effect ofcompound treatmenton CELF1protein levels. (A) CELF1
and a-tubulin protein levels were analysed on protein extracts from KB Telo
MyoD cells (DM1) following treatment with DMSO, Ro 31-8220 (10 mm), GF
109203X (10 mm) and chromomycin A3 (40 nm). (B) Histogram shows quanti-
fication of CELF1 protein normalized against a-tubulin levels. (C) CELF1
protein levels were analysed in western blot analysis of untreated and PKCa
knockdown extracts. PKCa inhibition was verified by western blot, normalized
against a-tubulin.
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Surprisingly, pentamidine was not identified as a hit within the
phosphatase inhibitor collection. This may be due to differences
in cell lines and/or compound concentrations used in our experi-
ments compared with those reported by Warf et al. (27) in which
pentamidine was first identified as potentially useful for DM
therapy.
Two compounds, chromomycin A3 from the NPC collection
and Ro 31-8220 from the kinase inhibitor library, reduced foci
in the primary screen and were validated in the secondary
screen. The identification of chromomycin A3 is particularly
interesting, as it has already been tested in clinical trials against
various indications. Analysis of chromomycin A3 and Ro
31-8220 in further assays provided insights to their effect on
other molecular features of DM. For example, treatment with
the compounds produced a redistribution of MBNL1 protein,
with a marked reduction in the nucleus, consistent with the
observed reduction of MBNL protein in foci. Furthermore, both
compounds produced a beneficial effect on the ratio of INSR
and ATP2A1 alternative splice isoforms, shifting the patterns
observed in DM cells to be more like those observed in non-DM
cells. However, although nuclear foci disappeared, as judged by
in situ hybridization for RNA and immuno-cytochemistry for
MBNL protein, the repeatexpansion transcripts werenot liberated
to the cytoplasm and remain in the nucleus of DM cells. This indi-
cates that the mutant transcripts are likely to be dispersed within
the nucleus yet remain trapped, perhaps due to some intrinsic
structural property of the repeat.
Nuclear foci consist of repeat expansion RNA complexed
with MBNL and probably other proteins that have yet to be iden-
tified. Our assay identifies compounds that eliminate such foci.
In effect, we are looking for a compound that will eliminate
foci, restore the nucleo-cytoplasmic balance of MBNL proteins
and correct DM-associated splicing abnormalities. Ideally, this
would be accompanied by export of the repeat expansion tran-
scripts or their degradation. However, it is not entirely clear
whether all aspects of the molecular pathophysiology would
have to be corrected for a compound to constitute a satisfactory
therapy for DM. Both chromomycin A3 and Ro 31-8220 have
some of the desired attributes of a DM therapy but further refine-
ment of their activity is required. The underlying mechanism by
which both compounds act on foci requires further investigation.
Chromomycin A3 is a glycosidic antibiotic that inhibits the
DNA-dependent RNA polymerase reaction by reversibly
binding to G-C base pairs to inhibit RNA synthesis (43). As it is
known that chromomycin, A3 interacts with GC-rich regions of
duplex DNA (44,45), it is possible that it also interacts with stem-
loop structures present in RNA foci. This binding interaction
could result in overall disruption of the stem-loop structure, and
hence facilitate the observed redistribution of MBNL1. One pos-
sible explanation for the effect of Ro 31-8220 treatment is that the
nuclear/cytoplasmic localization of MBNL1 is determined by a
phosphorylation event that is modified by Ro 31-8220. Additional
work will be required to confirm this possibility.
In a zebrafish repeat expansion model, the proportion of
phenotypically altered embryos was reduced following Ro
31-8220 treatment compared with non-treated embryos (Supple-
mentary Material, Fig. S7). This is consistent with the beneficial
effect of this inhibitor on the cardiac phenotype observed in a
DM1 mouse model (37). Ro 31-8220 is a PKC inhibitor and
recent work indicates that inappropriate activation of the PKC
pathway is a factor in DM pathogenesis (13,37). Kuyumcu-
Martinez et al. (13) have shown that PKC activation is detected
6 h after induction of repeat expansion transcripts in their mouse
model and that PKC activation results in hyper-phosphorylation
and increased steady-state levels of CELF1, although the phos-
phorylation site for PKC kinase within CELF1 remains to be
determined. Furthermore, these authors show that DM mis-
splicing events regulated by CELF1 are reduced by treatment
with PKC inhibitor Ro 31-8220, whereas those regulated by
MBNL1 are not. In the present study, however, we show that
ATP2A1 alternative splicing, which in muscle cells is MBNL1 de-
pendent (35), is altered following treatment with Ro 31-8220.
Thus, both CELF1- and MBNL1-related events are affected by
treatment with Ro 31-8220. The sequestration of MBNL proteins
innuclear foci andCELF1activation arekey events in the molecu-
lar pathogenesis of DM, though the direct connection between the
two has been difficult to establish. Our observations that Ro
31-8220 affects nuclear foci, MBNL1 distribution, ATP2A1 spli-
cing and CELF1 steady-state protein levels independently of PKC
activity suggests an additional target of this kinase inhibitor that
may link these two aspects of DM pathophysiology.
Kinase inhibitors are notoriously promiscuous and our study
shows that Ro 31-8220 acts to affect nuclear foci, MBNL-
dependent events and CELF1 protein levels independently of
PKC, suggesting that another kinase is involved. Indeed work
by others has shown the involvement of additional kinases in re-
sponse to repeat expansion RNA (46–48). Our data demonstrate
anunknowntargetof thiscompoundandpoints to the need to iden-
tify the specific target for this activity. Understanding more about
the activity of Ro 31-8220 may identify additional kinase involve-
ment in the progression of the condition.
Thus, in summary, we report a medium throughput assay
using in situ hybridization and high-content imaging to identify
compounds that may provide the starting point for future drug
development studies for DM therapy, and which provide pos-
sible alternatives to oligo-based approaches (25,28). The identi-
fication of Ro 31-8220 in our screen for compounds that affect
nuclear foci demonstrates an important role for this compound
on both MBNL- and CELF1-dependent events in DM, highlight-
ing it as a good starting point for a drug discovery programme.
METHODS ANDMATERIALS
Cell culture
Fibroblast cells were grown in Dulbecco’s modified eagles
medium (DMEM) with penicillin and streptomycin, and 10%
foetal calf serum (FCS) (Sigma). To differentiate fibroblasts,
the cells were plated in the same media with 1% FCS and
2 mg/ml doxycylin. Myoblast cultures were routinely grown in
Ham’s F10 containing penicillin and streptomycin with 20%
FCS (GIBCO) and differentiated in DMEM containing 1%
FCS. Repeat sizes were KBTeloMyoD—400 repeats,
DM1400—1400 repeats, DM15—3000 repeats, DM16—800
repeats and KagoTelo—3000–5000 repeats.
Small molecule libraries
Four different libraries were screened including 13 200 small
molecules from the Chembridge DiversetTM, 80 kinase inhibitors
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and 33 phosphatase inhibitors from Enzo Life Sciences. At the
time of screening, the NCGC NPC consisted of 2724 small mol-
ecule compounds, 52% of which are drugs approved for human
or animal use by the United States Food and Drug Administration,
22% are drugs approved in Europe, Canada or Japan, and the
remaining 26% are compounds that have entered clinical trials
or are research compounds commonly used in biomedical re-
search (49). Information on all four libraries can be obtained at
http://www.nottingham.ac.uk/~plzjdb/
Compound exposure
Cells were aliquoted into 384-well plates with 1.6 × 104 cells
per well with each compound screened in triplicate. For the
Chembridge Diverset library sequential dilution of compounds
was performed on a Tecan Evo Liquid handling robot to
produce a final concentration of 40 mm. For the NPC library,
compounds were tested in single-pass at three concentrations;
40, 8 and 1.6 mm in 384-well format. The kinase and phosphat-
ase libraries were screened in 96-well format with compound
concentrations of 100, 10, 1 mm and 100 nm. Secondary valid-
ation screens of all libraries were performed over a 12-point
dilution range, with a 1:3 dilution protocol, from 40 mm to
200 pm in 96-well format.
In situ hybridization protocol
Cells were exposed to compounds for 48 h after which in situ
hybridization was performed to identify foci using either a
Cy3- or Cy5-labelled (CAG)10 probe for DM1 or (CAGG)10
probe for DM2. Plates were analysed on a Molecular Devices
Micro High Content Imaging system, with nine fields imaged
per well to give 100 cells per well, per compound treatment.
The nuclear area was identified by Hoechst stain and the
number, size and intensity of foci was determined by scoring ad-
jacent pixels that were 80 greyscales or more above background.
Data were exported to an excel spreadsheet and the means and
standard deviations were calculated for the untreated controls
for comparison with each treatment on the same plate. The
Z-factor for this screening assay is 0.74 (mn ¼ 4.0682187,
mp ¼ 0.06273117, sn ¼ 0.40122691 and sp ¼ 0.03129234).
Assay for repeat expansion transcripts
Reverse transcription was performed using 1 mg total RNA from
compound-treated and untreated cells. PCR was carried out
using 1/20 of the synthesized cDNA with primers N11, 5′-C
ACTGTCGGACATTCGGGAAGGTGC and 133, 5′-GCTT
GCACGTGTGGCTCAAGCAGCTG. For Genescan analysis
primer N11 was labelled with FAM. Amplification was per-
formed with a Tm of 588C. The PCR product was subsequently
heated to 958C for 2 min followed by cooling to 48C. For BpmI
restriction digestion analysis of DMPK PCR products, 4 ml of
PCR mixture was digested overnight with restriction enzyme
BpmI (NEB) in a total reaction volume of 20 ml at 378C. The
final products were analysed by electrophoresis at 90 V with
3% agarose gels and the density of bands quantified using the
ImageJ software or by fragment analysis on an ABI377 sequen-
cer followed by Genescan quantification.
Alternative splicing assays
One mg of total RNA, extracted from cultured cells, was used as
a template for cDNA synthesis with random hexamers and
M-MuLV reverse transcriptase (NEB). One ml of cDNA was
used as a template for the PCR amplification with MegaMix
(Microzone) and the following primers: ATP2A1 forward—
5′-TTCGTTGCTCGGAACTACC and reverse—5′-GGTTGGG
AAGGGGAATTTAC; INSR forward—5′-CCAAAGACAGAC
TCTCAGAT and reverse 5′-AACATCGCCAAGGGACCTGC.
PCR amplification was performed under the following conditions:
958C for 5 min, followed by 32 cycles of 958C for 30 s, 608C for
30 s, 728C for 1 min and final extension at 728C for 5 min; The
PCR products were analysed by electrophoresis at 90 V with 3%
agarose gels and the density of bands was quantified using the
ImageJ software.
Western blots and detection
Western blotting was performed using a commercial NuPage
system (Invitrogen, UK) according to the manufacturer’s instruc-
tions. The four primary antibodies used in this study were MB1a
(50) (1:10 000 dilution), human CELF1 (3B1, Abcam, 1:2000 di-
lution), humana-tubulinandhuman LaminB (both obtained from
Santa Cruz and used at dilutions of 1:500). Anti-mouse IgG-
horseradish peroxidase was used as the secondary antibody. The
ImageJ software was used for the quantification of bands on
western blots.
Zebrafish model of myotonic dystrophy
The (CUG)140 repeat sequence was cloned into the pBluescript II
SK plasmid and transcribed into RNA using the Ambion mMes-
sage mMachine T7 Ultra kit. Embryos were injected with 50 pg
(CUG)140 RNA. (CUG)140 repeat injected embryos and uninjected
controls were treated with either 5 mm Ro 31-8220 or DMSO at
2 hpf. Compound was added directly to the fish water for 24 h.
The resulting phenotype was monitored at 26 hpf. To ensure direct
comparison measurements were established on somites from the
yolk cell extension to the end of the embryo tail. All compound
tests were conducted blind.
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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